

# *The International Vaccine Institute*

Financial statements

December 31, 2023 and 2022

## Index

	Page(s)
<b>Report of Independent Auditors</b> .....	<b>1-2</b>
<b>Financial statements</b>	
Statements of Financial Position .....	<b>3</b>
Statements of Activities .....	<b>4-5</b>
Statements of Functional Expenses .....	<b>6-7</b>
Statements of Cash Flows .....	<b>8</b>
Notes to the Financial Statements .....	<b>9-21</b>



## **Report of Independent Auditors**

To the Board of Trustees of  
The International Vaccine Institute

We have audited the accompanying financial statements of the International Vaccine Institute (the "IVI"), which comprise the statements of financial position as of December 31, 2023 and 2022, and the related statements of activities, statements of functional expenses and statements of cash flows for the years then ended.

### ***Management's Responsibility for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors' Responsibility***

Our responsibility is to express an opinion on the financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the IVI's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the IVI's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

***Opinion***

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the IVI as of December 31, 2023 and 2022 and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

March 29, 2024  
Seoul, Korea

**The International Vaccine Institute**  
**Statements of Financial Position**  
**As of December 31, 2023 and 2022**

	2023	2022
(In U.S. Dollars)		
<b>Assets</b>		
<i>Current assets</i>		
Cash and cash equivalents (Note 3,13)	\$ 27,465,350	\$ 33,280,048
Time deposits (Note 3,13)	29,928,031	21,510,422
Interest receivable (Note 3)	294,596	248,652
Contributions receivable, net (Note 4,13)	24,284,095	9,347,690
Other accounts receivables	104,288	80,036
Prepaid expenses	531,156	463,818
Loans to employees	44,050	48,880
Advanced payments	8,155	8,466
Other current assets (Note 8,13)	361,627	360,925
<b>Total Current Assets</b>	83,021,348	65,348,937
<i>Non-current assets</i>		
Long-term contributions receivable, net (Note 4)	722,656	1,724,670
Property and equipment, net (Note 6)	8,246,069	6,641,155
Intangible assets (Note 7)	12,300,408	12,659,544
Other non-current assets (Note 8)	499,775	361,342
<b>Total Non-current Assets</b>	21,768,908	21,386,711
<b>Total assets</b>	104,790,256	86,735,648
<b>Liabilities and net assets</b>		
<i>Current liabilities</i>		
Other accounts payable (Note 10)	3,273,688	4,456,809
Accrued expenses	1,828,353	1,604,170
Building deposit	50,173	51,561
<b>Total Current Liabilities</b>	5,152,214	6,112,540
<i>Non-current liabilities</i>	-	-
<b>Total liabilities</b>	5,152,214	6,112,540
<b>Net assets</b>		
Without donor restrictions (Note 9)	50,192,934	41,002,574
With donor restrictions (Note 9)	49,445,108	39,620,534
<b>Total net assets</b>	99,638,042	80,623,108
<b>Total liabilities and net assets</b>	\$ 104,790,256	\$ 86,735,648

The above statements of financial position should be read in conjunction with the accompanying notes.

**The International Vaccine Institute**  
**Statements of Activities**  
**For the Year Ended December 31, 2023**

(In U.S. Dollars)	Without Donor Restriction	With Donor Restriction	Total
<b>Revenues</b>			
Contributions	\$ 22,998,085	\$ 65,353,464	\$ 88,351,549
Cash and other financial assets	22,998,085	65,353,464	88,351,549
Other income (Note 11)	112,953	15	112,968
Interest income (Note 5)	638,392	1,102,464	1,740,856
Foreign exchange gain	2,252,253	137,777	2,390,030
Net assets released from restrictions			
Satisfaction of program restrictions	56,686,232	(56,686,232)	-
Satisfaction of equipment acquisition restrictions	41,039	(41,039)	-
Expiration of time restrictions	-	-	-
Appropriation from donor endowment and subsequent satisfaction of any related donor restrictions	41,875	(41,875)	-
Total net assets released from restrictions	<u>56,769,146</u>	<u>(56,769,146)</u>	<u>-</u>
Total revenues	<u>82,770,829</u>	<u>9,824,574</u>	<u>92,595,403</u>
<b>Expenses</b>			
Program Cholera	5,886,254	-	5,886,254
Program Typhoid	3,079,823	-	3,079,823
Program Chikungunya	1,504,165	-	1,504,165
Program HPV	4,212,169	-	4,212,169
Program Covid-19	18,608,129	-	18,608,129
Program Streptococcal A Vaccine	818,682	-	818,682
Program Others	15,901,358	-	15,901,358
Management and general	21,100,948	-	21,100,948
Foreign exchange loss	2,468,941	-	2,468,941
Total expenses	<u>73,580,469</u>	<u>-</u>	<u>73,580,469</u>
Change in net assets	9,190,360	9,824,574	19,014,934
Net assets at the beginning of year	41,002,574	39,620,534	80,623,108
Net assets at the end of year	<u>\$ 50,192,934</u>	<u>\$ 49,445,108</u>	<u>\$ 99,638,042</u>

The above statements of activities should be read in conjunction with the accompanying notes.

**The International Vaccine Institute**  
**Statements of Activities**  
**For the Year Ended December 31, 2022**

(In U.S. Dollars)	Without Donor Restriction	With Donor Restriction	Total
<b>Revenues</b>			
Contributions	\$ 10,548,212	\$ 66,467,432	\$ 77,015,644
Cash and other financial assets	10,548,212	66,467,432	77,015,644
Other income (Note 11)	269,467	2	269,469
Interest income (Note 5)	175,251	311,251	486,502
Foreign exchange gain	1,304,588	191,223	1,495,811
Net assets released from restrictions			
Satisfaction of program restrictions	54,747,022	(54,747,022)	-
Satisfaction of equipment acquisition restrictions	325,581	(325,581)	-
Expiration of time restrictions	-	-	-
Appropriation from donor endowment and subsequent satisfaction of any related donor restrictions	945,825	(945,825)	-
Total net assets released from restrictions	<u>56,018,428</u>	<u>(56,018,428)</u>	<u>-</u>
Total revenues	<u>68,315,946</u>	<u>10,951,480</u>	<u>79,267,426</u>
<b>Expenses</b>			
Program Cholera	5,144,735	-	5,144,735
Program Typhoid	2,891,776	-	2,891,776
Program Chikungunya	2,946,506	-	2,946,506
Program HPV	794,936	-	794,936
Program Covid-19	24,597,707	-	24,597,707
Program Others	12,201,354	-	12,201,354
Management and general	13,709,202	-	13,709,202
Foreign exchange loss	3,109,540	-	3,109,540
Total expenses	<u>65,395,756</u>	<u>-</u>	<u>65,395,756</u>
Change in net assets	2,920,190	10,951,480	13,871,670
Net assets at the beginning of year	<u>38,082,384</u>	<u>28,669,054</u>	<u>66,751,438</u>
Net assets at the end of year	<u>\$ 41,002,574</u>	<u>\$ 39,620,534</u>	<u>\$ 80,623,108</u>

The above statements of activities should be read in conjunction with the accompanying notes.

**The International Vaccine Institute**  
**Statements of Functional Expenses**  
**For the Year Ended December 31, 2023**

(In U.S. Dollars)	Program Services							Support Services		
	Cholera	Typhoid	Chikungunya	HPV	Covid-19	Streptococcal A Vaccine	Other	Total program services	Management and General	Total
Salaries & Benefits	\$ 1,505,569	\$ 889,488	\$ 523,782	\$ 551,385	\$ 3,908,189	\$ 125,246	\$ 4,944,081	\$ 12,447,740	\$ 7,581,047	\$ 20,028,787
Travel Expense	230,276	147,343	11,525	153,720	231,903	43,389	1,107,499	1,925,655	1,719,103	3,644,758
Service expenses	223,203	220,545	55,230	122,152	772,692	24,455	3,962,289	5,380,566	3,131,316	8,511,882
Sub-Awards	3,578,285	1,773,933	907,882	2,695,086	11,018,640	621,715	4,025,860	24,621,401	3,987,389	28,608,790
Supplies	340,292	44,869	4,249	678,088	2,009,315	2,761	1,555,414	4,634,988	915,405	5,550,393
Building Expenses	-	-	-	-	-	-	-	-	2,160,295	2,160,295
Depreciation	4,132	-	-	-	36,908	-	-	41,040	988,174	1,029,214
Amortization	-	-	-	-	-	-	-	-	359,136	359,136
Other (Note 12)	4,497	3,645	1,497	11,738	630,482	1,116	306,215	959,190	259,083	1,218,273
<b>Total expenses</b>	<b><u>\$ 5,886,254</u></b>	<b><u>\$ 3,079,823</u></b>	<b><u>\$ 1,504,165</u></b>	<b><u>\$4,212,169</u></b>	<b><u>\$ 18,608,129</u></b>	<b><u>\$ 818,682</u></b>	<b><u>\$ 15,901,358</u></b>	<b><u>\$ 50,010,580</u></b>	<b><u>\$ 21,100,948</u></b>	<b><u>\$ 71,111,528</u></b>

The above statements of functional expenses should be read in conjunction with the accompanying notes.



**The International Vaccine Institute**  
**Statements of Functional Expenses**  
**For the Year Ended December 31, 2022**

(In U.S. Dollars)	Program Services						Support Services	Total	
	Cholera	Typhoid	Chikungunya	HPV	Covid-19	Other	Total program services		Management and General
Salaries & Benefits	\$ 1,089,522	\$ 938,199	\$ 547,576	\$ 285,984	\$ 4,016,346	\$ 4,251,492	\$ 11,129,119	\$ 5,315,353	\$ 16,444,472
Travel Expense	174,386	314,058	42,621	55,560	304,305	735,502	1,626,432	605,304	2,231,736
Service expenses	217,426	359,678	51,541	27,426	658,708	2,853,422	4,168,201	2,325,647	6,493,848
Sub-Awards	3,548,566	1,215,657	2,299,952	388,279	17,663,712	3,020,099	28,136,265	307,768	28,444,033
Supplies	98,541	31,250	3,081	33,152	1,663,360	1,199,006	3,028,390	633,482	3,661,872
Building Expenses	-	-	-	-	-	-	-	1,786,847	1,786,847
Depreciation	7,271	4,439	-	-	264,598	49,273	325,581	763,141	1,088,722
Amortization	-	-	-	-	-	-	-	359,136	359,136
Other (Note 12)	9,023	28,495	1,735	4,535	26,678	92,560	163,026	1,612,524	1,775,550
<b>Total expenses</b>	<b>\$ 5,144,735</b>	<b>\$ 2,891,776</b>	<b>\$ 2,946,506</b>	<b>\$ 794,936</b>	<b>\$ 24,597,707</b>	<b>\$ 12,201,354</b>	<b>\$ 48,577,014</b>	<b>\$ 13,709,202</b>	<b>\$ 62,286,216</b>

The above statements of functional expenses should be read in conjunction with the accompanying notes.

**The International Vaccine Institute**  
**Statements of Cash Flows**  
**For the Years Ended December 31, 2023 and 2022**

	2023	2022
(In U.S. Dollars)		
<b>Cash flows from operating activities</b>		
Change in net assets	\$ 19,014,934	\$ 13,871,670
Adjustments to reconcile change in net assets to net cash from(used in) operating activities		
Depreciation	1,029,213	1,088,722
Amortization	359,136	359,136
Bad debt expenses	-	1,368,980
Others	636	1
Loss(Gain) on foreign currency translation	27,877	1,383,104
Increase in accrued interest	(45,944)	(237,324)
Increase in contributions receivable	(13,975,832)	(976,975)
Increase in accounts receivable-other	(24,716)	(59,178)
Increase in prepaid expenses	(67,338)	(114,253)
Decrease(increase) in loans to employees	4,830	(13,165)
Increase in other assets	(150,247)	(254,160)
Decrease(increase) in advanced payment	311	(5,466)
Increase(decrease) in accounts payable-other	(1,462,492)	1,275,379
Increase(decrease) in advance payments received	-	(4,977)
Increase(decrease) in accrued expenses	224,183	(15,178)
Repayment of building deposit	-	(7,587)
Net cash inflow from operating activities	4,934,551	17,658,729
<b>Cash flows from investing activities</b>		
Increase of time deposits	(29,928,031)	(21,705,948)
Decrease of time deposits	21,510,422	16,418,931
Purchase of property and equipment	(2,341,168)	(2,345,236)
Net cash outflow from investing activities	(10,758,777)	(7,632,253)
<b>Cash flows from financing activities</b>	-	-
Net cash inflow from financing activities	-	-
<b>Changes in cash and cash equivalents due to foreign currency translation</b>	9,528	(942,810)
<b>Net increase(decrease) in cash and cash equivalents</b>	(5,814,698)	9,083,666
<b>Cash and cash equivalents at the beginning of the year</b>	33,280,048	24,196,382
<b>Cash and cash equivalents at the end of the year</b>	\$ 27,465,350	\$ 33,280,048

The above statements of cash flows should be read in conjunction with the accompanying notes.

**The International Vaccine Institute**  
**Notes to the Financial Statements**  
**December 31, 2023 and 2022**

**1. Nature of Activities**

The International Vaccine Institute (the “IVI”) located in Seoul, Republic of Korea, is an independent international organization established at the initiative of the United Nations Development Programme (UNDP) under the Vienna Convention of 1969 through a treaty signed by Signatory Countries. Signatories and/or State Parties to the IVI Establishment Agreement include the World Health Organization (WHO) and 39 signatory countries. IVI’s mission is to discover, develop, and deliver safe, effective and affordable vaccines for global public health.

IVI’s registered office is located in Seoul National University Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea. The number of employees as of December 31, 2023 is 245.

The Korean National Assembly ratified IVI’s Headquarters Agreement between the Republic of Korea and IVI on December 1, 1998.

**2. Summary of Significant Accounting Policies**

The significant accounting policies followed by IVI in the preparation of its financial statements are summarized below:

**Basis of Financial Statement Presentation**

IVI’s financial statements have been prepared on the accrual basis of accounting under accounting principles generally accepted in the United States of America (U.S. GAAP). IVI primarily generates and expends cash in U.S. Dollars which is its measurement currency. All amounts are presented in U.S. Dollars, unless indicated otherwise.

The classification of a not-for-profit organization's net assets and its support, revenue and expenses is based on the existence or absence of donor-imposed restrictions. It requires that the amounts for each of the classes of net assets be displayed in the Statements of Financial Position and that the amounts of change in each of those classes of net assets be displayed in the Statements of Activities.

**Revenue Recognition**

**Revenue recognition (conditional)**

Conditional promises to give shall be recognized when the condition or conditions are substantially met.

**Revenue recognition (unconditional)**

An unconditional promise to give shall be recognized when it is received. However, to be recognized there must be sufficient evidence in the form of verifiable documentation that a promise was made and received. In cases of ambiguous donor stipulations, a contribution containing stipulations that are not clearly unconditional shall be presumed to be a conditional contribution.

### **Intangible Assets (In-kind contribution)**

IVI received rights to use certain assets for free without legal title passing to IVI. Such rights are recorded as intangible asset at its estimated fair value at the date of transfer, if the rights received i) create or enhance nonfinancial assets or ii) require specialized skills, are provided by individuals possessing those skills and would need to be purchased if not provided by donation. Amortization is computed using the straight-line method based on estimated useful lives ranging from 1-55 years.

### **Sub-awards Expenditure**

Sub-awards expenditures are recognized as incurred.

### **Cash, Cash Equivalents and Bank Deposits**

IVI holds deposits at several banks with high credit ratings. Bank deposits are stated at cost and accrued interest from the deposits is added to the principal.

### **Contributions Receivable**

Unconditional promises to give are recognized initially at present value as contributions revenue in the period such promises are made by donors. Present value is estimated giving consideration to anticipated future cash receipts and discounting such amounts at a risk-adjusted rate commensurate with the duration of the donor's payment plan. In subsequent periods, the discount rate is unchanged and the allowance for uncollectible contributions is reassessed and adjusted if necessary. The amortization of the discounts is recorded as additional contribution revenue.

### **Prepaid Expenses**

Prepaid expense is the amount paid in advance, which will be recognized as an expense following the passage of time.

### **Loans to Employees**

Loans to employee are repaid through monthly salaries of the employees, which are generally provided to internationally recruited employees for their housing rental deposit.

### **Advanced Payment**

Advanced payment is the amount paid for the official purpose of employees or consultants, which will be recognized as expense after receiving expense reports.

### **Property and Equipment**

Property and equipment are stated at cost less accumulated depreciation. Routine maintenance and repairs are expensed as incurred. Subsequent expenditures on property and equipment are capitalized when the condition of the asset is improved beyond originally assessed standard of performance. Depreciation is computed using the straight-line method based on estimated useful lives ranging from 1 to 10 years.

### **Guarantee Deposits**

Guarantee deposits are lump sums paid based on a contract for the right to use assets. The deposits will be refunded after expiration of the contract or at the time of early termination of the contract by IVI. The deposits due on demand are carried at their nominal amount.

### **Foreign Currency Translation**

Monetary foreign currency assets and liabilities have been translated into U.S. Dollar equivalents using the current exchange rates in effect on December 31, 2023 and 2022, respectively. Foreign currency transactions are translated into U.S. Dollar using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the translation and from settlement of such transactions are recognized. IVI separately discloses the gross effects of changes in foreign exchange rates in the statement of activities.

### **Retirement Benefits**

IVI sponsors defined contribution plans for certain employees. IVI makes pension deposits, which amount to 15 percent of monthly salary. Retirement benefits are paid to employees from the pension deposits. IVI's contributions relating to defined contribution plans amount to US\$ 1,939,021 in 2023 (2022: US\$ 1,610,801).

### **Net Assets**

A statement of financial position shall focus on the not-for-profit as a whole and shall report net assets classified based on the restrictions. The amounts for each of two classes of net assets with donor restrictions, without donor restriction are based on the existence or absence of donor-imposed restrictions.

#### 1) Net assets with donor restrictions

Net assets with donor restrictions are based on the existence of donor-imposed restrictions.

#### 2) Net assets without donor restrictions

Net assets without donor restrictions are based on the absence of donor-imposed restrictions.

### **Capital fund**

The capital fund is appropriated by the transfers from 'Undesignated asset' based on IVI's decision and it is the main source for future acquisition of property and equipment.

### **Undesignated asset**

The undesignated asset represents the accumulated net asset changes of IVI's revenue over expenses and is used to meet ongoing operating requirements. This includes intangible asset, IVI building right to use.

### 3. Cash and cash equivalents and Bank Deposits

Cash and cash equivalents and bank deposits as of December 31, 2023 and 2022 consists of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Cash and cash equivalents		
Demand deposits	\$ 20,620,686	\$ 22,348,751
MMDA	<u>6,844,664</u>	<u>10,931,297</u>
	<u>27,465,350</u>	<u>33,280,048</u>
Bank deposits		
Time deposits	<u>29,928,031</u>	<u>21,510,422</u>
	<u>29,928,031</u>	<u>21,510,422</u>
	<u>\$ 57,393,381</u>	<u>\$ 54,790,470</u>

Accrued interest income of US \$294,596 was recognized for time deposits as of December 31, 2023 (December 31 2022: US \$248,652)

### 4. Contributions receivable

Contributions receivable as of December 31, 2023 and 2022 consists of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Contributions receivable		
Less than one year	\$ 24,284,095	\$ 9,342,884
One to five years	<u>771,885</u>	<u>1,722,270</u>
	25,055,980	11,065,154
Less unamortized discount	<u>(49,229)</u>	<u>7,206</u>
Total contributions receivable, net	25,006,751	11,072,360
Less current contributions receivable	<u>(24,284,095)</u>	<u>(9,347,690)</u>
Total long-term contributions receivable	<u>\$ 722,656</u>	<u>\$ 1,724,670</u>

Long term contributions receivables have been discounted to present value using the interest rate of 3-year Republic of Korea Government bonds.

### 5. Investment Income

IVI's interest income of US\$ 1,637,686 occurs from time deposits for the year ended Dec 31, 2023(2022: US\$ 478,589).

## 6. Property and equipment

Changes in Property and equipment for the years ended December 31, 2023 and 2022 are as follows:

	2023				
	January 1	Additions & Depreciation	Disposals	Replacement	December 31
<i>(In U.S. Dollars)</i>					
Acquisition cost:					
Office and building equipment	\$ 5,273,502	\$ 1,236,944	\$ (12,673)	\$ 30,153	\$ 6,527,926
Leasehold improvements	481,440	714,516	-	-	1,195,956
Computer equipment	2,095,191	70,016	(226,352)	-	1,938,855
Vehicles	43,364	-	-	-	43,364
Laboratory equipment	2,143,253	-	(51,511)	-	2,091,742
Scientific equipment	3,400,617	486,823	(10,998)	-	3,876,442
Project equipment	1,492,506	56,257	(635)	-	1,548,128
Construction in progress	30,153	70,210	-	(30,153)	70,210
	<u>14,960,026</u>	<u>2,634,766</u>	<u>(302,169)</u>	<u>-</u>	<u>17,292,623</u>
Accumulated depreciation:					
Office and Building equipment	1,567,765	497,385	(12,673)	-	2,052,477
Leasehold improvements	218,025	43,580	-	-	261,605
Computer equipment	1,744,517	117,457	(226,348)	-	1,635,626
Vehicles	42,642	722	-	-	43,364
Laboratory equipment	2,143,253	-	(51,511)	-	2,091,742
Scientific equipment	1,136,302	329,030	(10,998)	-	1,454,334
Project equipment	1,466,367	41,039	-	-	1,507,406
	<u>8,318,871</u>	<u>1,029,213</u>	<u>(301,530)</u>	<u>-</u>	<u>9,046,554</u>
Net book value	<u>6,641,155</u>	<u>1,605,553</u>	<u>(639)</u>	<u>-</u>	<u>8,246,069</u>
	2022				
	January 1	Additions & Depreciation	Disposals	Replacement	December 31
<i>(In U.S. Dollars)</i>					
Acquisition cost:					
Office and building equipment	\$ 3,098,787	\$ 1,307,403	\$ (5,248)	\$ 872,560	\$ 5,273,502
Leasehold improvements	471,126	10,314	-	-	481,440
Computer equipment	1,816,688	278,503	-	-	2,095,191
Vehicles	43,364	-	-	-	43,364
Laboratory equipment	2,387,086	-	(243,833)	-	2,143,253
Scientific equipment	2,713,359	688,411	(1,153)	-	3,400,617
Project equipment	1,482,170	30,452	(20,116)	-	1,492,506
Construction in progress	872,560	30,153	-	(872,560)	30,153
	<u>12,885,140</u>	<u>2,345,236</u>	<u>(270,350)</u>	<u>-</u>	<u>14,960,026</u>
Accumulated depreciation:					
Office and Building equipment	1,215,371	357,641	(5,247)	-	1,567,765
Leasehold improvements	175,587	42,438	-	-	218,025
Computer equipment	1,659,517	85,000	-	-	1,744,517
Vehicles	33,969	8,673	-	-	42,642
Laboratory equipment	2,387,086	-	(243,833)	-	2,143,253
Scientific equipment	868,066	269,389	(1,153)	-	1,136,302
Project equipment	1,160,902	325,581	(20,116)	-	1,466,367
	<u>7,500,498</u>	<u>1,088,722</u>	<u>(270,349)</u>	<u>-</u>	<u>8,318,871</u>
Net book value	<u>\$ 5,384,642</u>	<u>\$ 1,256,514</u>	<u>\$ (1)</u>	<u>\$ -</u>	<u>\$ 6,641,155</u>

## 7. Intangible assets

Changes in Intangible assets for the years ended December 31, 2023 and 2022 are as follows:

	2023			December 31
	January 1	Additions & Amortization	Disposals	
(In U.S. Dollars)				
Acquisition cost:				
Intangible assets	\$ 19,752,479	\$ -	\$ -	\$ 19,752,479
– Building right	<u>19,752,479</u>	<u>-</u>	<u>-</u>	<u>19,752,479</u>
Accumulated amortization:				
Building right	7,092,935	359,136	-	7,452,071
	<u>7,092,935</u>	<u>359,136</u>	<u>-</u>	<u>7,452,071</u>
Net book value	<u>\$ 12,659,544</u>	<u>\$ (359,136)</u>	<u>\$ -</u>	<u>\$ 12,300,408</u>
	2022			December 31
	January 1	Additions & Amortization	Disposals	
(In U.S. Dollars)				
Acquisition cost:				
Intangible assets	\$ 19,752,479	\$ -	\$ -	\$ 19,752,479
– Building right	<u>19,752,479</u>	<u>-</u>	<u>-</u>	<u>19,752,479</u>
Accumulated amortization:				
Building right	6,733,799	359,136	-	7,092,935
	<u>6,733,799</u>	<u>359,136</u>	<u>-</u>	<u>7,092,935</u>
Net book value	<u>\$ 13,018,680</u>	<u>\$ (359,136)</u>	<u>\$ -</u>	<u>\$ 12,659,544</u>



## 8. Other assets

Other current and non-current assets as of December 31, 2023 and 2022 consist of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Current guaranteed deposits	\$ 361,627	\$ 360,925
	<u>\$ 361,627</u>	<u>\$ 360,925</u>

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Non-current guaranteed deposits	\$ 401,225	\$ 234,244
Telephone subscription rights	2,299	2,299
Other receivable	96,251	124,799
	<u>\$ 499,775</u>	<u>\$ 361,342</u>

## 9. Net assets

(1) Net assets without donor restrictions as of December 31, 2023 and 2022 consists of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Capital fund(*1)	\$ 5,212,162	\$ 5,212,162
Undesignated(*2)	44,980,772	35,790,412
	<u>\$ 50,192,934</u>	<u>\$ 41,002,574</u>

(\*1) The capital fund is appropriated by the transfers from 'undesignated asset'

(\*2) Undesignated Asset includes intangible asset, IVI building right to use, and the amount is US\$ 12,300,408 as of end of 2023 (2022: US\$ 12,659,544). And it includes right to receive which has not been paid in cash.

(2) Net assets with donor restrictions as of December 31, 2023 and 2022 consists of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Cholera	\$ 3,685,411	\$ 4,456,202
Typhoid	5,381,509	7,758,779
Chikungunya	2,640,009	500,765
HPV	2,982,564	6,040,329
COVID-19	9,940,166	8,853,394
Streptococcal A Vaccine	663,979	-
Others	24,151,469	12,011,065
	<u>\$ 49,445,108</u>	<u>\$ 39,620,534</u>

(3) Changes in net assets with donor restrictions are as follows, separately by the large amount of each program.

(In U.S. Dollars)	2023	2022
Net assets at the beginning of the year	\$ 39,620,534	\$ 28,669,054
Increase:		
SK-COVID-19 vaccine clinical trial phase3 [COCOBA]	11,386,283	16,110,515
Biorepository Project	6,243,777	-
VAT08 Cov19 Phase3 study Sanofi Pasteur in Nepal	5,050,857	2,245,394
Global Training Hub for Biomanufacturing (GTH-B)	4,027,823	2,528,361
CEPI GCCDP	3,856,588	1,591,868
Phase 2a - safety and immunogenicity of Hecolin	3,338,158	-
ECOVA	2,808,650	1,435,624
STP2250 Phase 1/2a study	2,477,293	-
ALERT-WA	2,328,862	-
Vaccine R&D Support of IVI	2,314,270	-
Phase I clinical trial of CCV(RIGHT)_Part II	1,586,276	-
BMGF_Hecolin(HEV) in Pakistan for Pregnant women	1,522,086	1,733,046
Enhancing Cholera Control in Nepal and Mozambique	1,319,255	1,772,042
Strep A Vaccine Global Consortium 2.0 (SAVAC2)	1,300,034	-
OP_Phase 2a - safety and immunogenicity of Hecolin	1,207,376	-
VAD00004 RSV Ph3 trial in Nepal	1,129,052	-
Fleming Regional Grant I	995,120	771,942
LTFU of OCV-S Phase 3 Study	946,097	-
Global Human Papillomavirus Burden Study(LSHTM)_II	936,257	1,944,746
OCVs_Product licensure	826,866	1,172,408
Establishment of platform technology	786,652	172,044
RAPCOID	742,178	-
Fleming Regional Grant II	688,696	736,913
OCV-S_Technology Transfer_Biovac	600,292	240,677
VASA (Vaccine Against Schistosomiasis for Africa)	579,466	416
Global Human Papillomavirus Burden Study(IVI)_I	533,453	3,068,057
Toxicity study for trivalent Typhi/iNTS vaccine	513,332	989,301
USP Hands-on Training in Vaccine Manufacturing	500,419	-
Pre-clinical study of Adenovirus type 55 vaccine	494,777	231,862
FVVA for iNTS	410,424	653,744
Technical Assistance Support to THECA Studies	370,433	566,057
Vi-DT clinical development support for SK	359,840	2,243
Vaccinology Course	349,501	90,895
Development of a S. Paratyphi A / S Typhi bivalent	337,297	222,316
J&J heterologous prime booster study in Thailand	318,072	908,051
Strep A Vaccine Global Consortium 2.0 (SAVAC2)	303,684	-
Environmental surveillance for typhoid in Fiji	288,667	1,213,426
EQAsia	248,240	222,547
Mutiple projects with ICDDR,B	237,620	309,144
Development of bivalent vaccine for SFTS and HFRS	230,938	239,789
Establishment of technology supporting base system	229,972	111,740
KDCA Fellowship Program for EPIC studies	223,335	220,757
The development of new liposome-based adjuvant	218,207	205,845
mRNA vaccine platform against Lassa Fever	215,571	64,175
IVI - SK bioscience Park Mahnhoon Award	207,430	177,576
Assessment of immunogenicity of EuCorVac-19vaccine	204,167	7,969
The establishment of GCLP lab in GBI	191,643	-
nAb titer assessment of SK Bioscience's GBP510	179,202	171,968
Assessment of neutralizing antibodies for SARS-CoV	168,614	13,756
ASAVI-SAVAC IPDP	165,000	154,130
Mucosal influenza vaccines using microneedle patch	154,614	173,459
Ethiopia Cholera Control and Prevention(ECCP)(KSC)	154,427	213,337

(In U.S. Dollars)	2023	2022
Extended analyses of datasets of cholera/typhoid	148,592	147,419
Phase I Vacc-iNTS	148,523	-
nAb titer assessment of SKB's NBP622 vaccine	145,222	-
Stage II development of DuoChol_Wellcom Trust	142,742	-
Development of Novel DisinfectionReinforcementTech	114,527	12,944
Assessment of immunogenicity COVID-19 microneedle	114,463	-
Vaccine Impact Modeling Consortium (VIMC)	109,540	199,209
Hecolin(HEV) in Pakistan for Pregnant women	107,774	4,035,683
Cholera Vaccines Standards and reagents	101,764	4,628
EdJen COVID19 vaccine development	101,179	195,475
Evaluation of ST pharm mRNA vaccine efficacy	101,175	-
OCV BBC Documentary	100,435	-
Challenge study against SARS-CoV-2	81,524	56,056
Development of nanoparticle-based vaccine adjuvant	81,355	39,617
[IDB] KOR-IDB Biomanufacturing Training	81,022	-
Assessment of neutralizing Ab titer for COVID-19	75,881	81,311
Assessment of Binding Antibodies Induced bySTP2250	13,408	-
Optimization and preclinical development of TB	73,013	151,245
Development of MERS&CCHFV vaccine based on rVSV	72,038	184,778
Evaluation of immunity of SFTS and HFRS vaccines	62,583	-
Vi-DT Phase 3 Clinical Development Support	56,936	10,660
Surveillance for TVC impact assessment in Africa	54,337	2,170,779
Others	(2,301,455)	16,991,964
Sub total	<u>66,593,721</u>	<u>66,969,908</u>
Decrease :		
SK-COVID-19 vaccine clinical trial phase3 [COCOA]	12,841,829	17,441,571
Global Training Hub for Biomanufacturing (GTH-B)	3,342,196	3,172,017
ECOVA	2,610,459	2,178,715
VAT08 Cov19 Phase3 study Sanofi Pasteur in Nepal	2,168,143	2,723,680
Typhoid & Japanese Encephalitis (Fiji,Mozam,Timor)	2,083,413	1,177,032
Global Human Papillomavirus Burden Study(IVI)_I	1,995,665	31,014
Stage II development of DuoChol_Wellcom Trust	1,959,484	-
Global Human Papillomavirus Burden Study(LSHTM)_II	1,939,779	-
CEPI GCCDP	1,717,344	3,356,360
Surveillance for TVC impact assessment in Africa	1,280,956	-
Phase I clinical trial of CCV(OP)_Part I	1,217,321	578,130
Hecolin(HEV) in Pakistan for Pregnant women	1,003,088	170,314
Enhancing Cholera Control in Nepal and Mozambique	935,420	707,165
INO-4800 Phase1/2	907,425	759,583
BMGF_Hecolin(HEV) in Pakistan for Pregnant women	893,124	73,611
Strep A Vaccine Global Consortium 2.0 (SAVAC2)	846,480	-
Multi-country TSP(The Severe Typhoid in Africa)	845,875	1,640,259
Fleming Regional Grant I	839,266	1,342,412
Establishment of platform technology	726,511	504,342
Thailand HPV Vaccine Single Dose Impact Study	618,723	859,878
Phase I clinical trial of CCV(RIGHT)_Part II	614,028	1,122,204
OCVs_Product licensure	607,618	609,655
STP2250 Phase 1/2a study	572,344	-
Environmental surveillance for typhoid in Fiji	531,608	406,637
Oral Cholera Vaccine reformulation	515,337	1,763,451
Sm-p80 vaccine for schisto_phase 1b/2a	509,931	-
Pre-clinical study of Adenovirus type 55 vaccine	500,752	239,365
FVVA for iNTS	492,613	424,714
OP_Phase 2a - safety and immunogenicity of Hecolin	467,572	-

(In U.S. Dollars)	2023	2022
J&J heterologous prime booster study in Thailand	467,124	942,012
Fleming Regional Grant II	453,777	837,166
Toxicity study for trivalent Typhi/iNTS vaccine	441,175	942,253
Technical Assistance Support to THECA Studies	420,206	501,532
OCV-S_Technology Transfer_Biovac	403,262	11,063
USP Hands-on Training in Vaccine Manufacturing	402,039	-
VASA (Vaccine Against Schistosomiasis for Africa)	386,939	268,569
HHT (Household Transmission of SARS-CoV-2)	340,786	1,328,457
IVI Next Horizon Strategic Support	325,000	-
Development of a S. Paratyphi A / S Typhi bivalent EQAsia	303,704	215,721
KDCA Fellowship Program for EPIC studies	276,575	303,155
mRNA vaccine platform against Lassa Fever	258,764	40,769
Vaccinology Course	253,351	169,978
Phase I Vacc-iNTS	250,772	218,233
Assessment of neutralizing antibodies for SARS-CoV	222,780	-
Development of bivalent vaccine for SFTS and HFRS	221,025	44,588
Vi-DT clinical development support for SK	217,596	239,379
Vaccine development against MERS-CoV	217,071	411,427
Mutiple projects with ICDDR,B	201,034	-
Establishment of technology supporting base system	197,009	109,842
The development of new liposome-based adjuvant	195,805	95,708
The establishment of GCLP lab in GBI	190,158	197,380
IVI - SK bioscience Park Mahnhoon Award	188,793	-
nAb titer assessment of SK Bioscience's GBP510	187,086	181,319
International Hepatitis E Symposium	181,832	14,370
COVID-19 research in African settings (COVIA)	178,132	19,549
Vi-DT Phase 3 Clinical Development Support	178,132	19,549
Mucosal influenza vaccines using microneedle patch	153,712	(58,699)
VAD00004 RSV Ph3 trial in Nepal	145,259	30,358
Vaccine Impact Modeling Consortium (VIMC)	137,154	143,341
Extended analyses of datasets of cholera/typhoid	127,007	-
SVCF Open Philanthropy_VASA additional support	125,947	164,119
Assessment of therapeutic effect of CT-P59	125,426	191,735
Development of nanoparticle-based vaccine adjuvant	123,892	17,092
EdJen COVID19 vaccine development	121,710	32,249
Pre-clinical Studie with Covid-19 VaccineCandidate	115,260	75,539
LTFU of OCV-S Phase 3 Study	111,492	113,961
Hepatitis B Vaccine Ph1 Study with QuadMedicine	104,941	139,914
Development of Novel DisinfectionReinforcementTech	104,652	-
Strep A Vaccine Global Consortium 2.0 (SAVAC2)	96,765	57,031
Hep E Immunogenicity and Safety Study - Planning	93,259	-
Ethiopia Cholera Control and Prevention(ECCP)(KSC)	92,276	8,924
Assessment of immunogenicity of EuCorVac-19vaccine	88,597	280,138
ASAVI-SAVAC IPDP	85,418	236,378
Efficacy of Influenza mRNA vaccine in mice	76,464	27,160
Immunogenicity assesment of plantbased ptn vaccine	75,192	-
ALERT-WA	68,203	3,583
US-Japan Cholera Conference	67,905	-
[IDB] KOR-IDB Biomanufacturing Training	67,897	5,401
Evaluation of prophylactic and therapeuticEfficacy	67,517	-
Evaluation of immunity of SFTS and HFRS vaccines	66,632	-
ELISA of CT-QTP104--2	62,851	-
Development of microneedle array patch, MR vaccine	62,022	29,249
Cholera Vaccines Standards and reagents	58,365	-
	58,048	76,280

(In U.S. Dollars)	<u>2023</u>	<u>2022</u>
COVID-19 pseudovirus neut system (KSC)	57,161	14,645
Challenge study against SARS-CoV-2	56,471	15,504
Process Development & Scale-up Activities Vi-DT SK	51,494	294,096
Vi-DT clinical development support for PT Biofarma	50,030	24,667
Others	<u>801,206</u>	<u>5,587,824</u>
Sub total	<u>56,769,147</u>	<u>56,018,428</u>
<b>Net assets at the end of the year</b>	<u>\$ 49,445,108</u>	<u>\$ 39,620,534</u>

#### 10. Other accounts payable

Other accounts payable as of December 31, 2023 and 2022 consists of the following:

(In U.S. Dollars)	<u>2023</u>	<u>2022</u>
Other accounts payable – vendors	\$ 3,042,459	\$ 4,185,372
Other payable – employee	157,190	213,950
Other payable – others	<u>74,039</u>	<u>57,487</u>
	<u>\$ 3,273,688</u>	<u>\$ 4,456,809</u>

#### 11. Other income

Other income for the year ended December 31, 2023 consists of the following:

(In U.S. Dollars)	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>
Lease revenue	\$ 56,947	\$ -
Miscellaneous	<u>56,006</u>	<u>15</u>
	<u>\$ 112,953</u>	<u>\$ 15</u>

Other income for the year ended December 31, 2022 consists of the following:

(In U.S. Dollars)	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>
Lease revenue	\$ 56,171	\$ -
Miscellaneous	<u>213,296</u>	<u>2</u>
	<u>\$ 269,467</u>	<u>\$ 2</u>

## 12. Other expenses

Other expenses for the years ended December 31, 2023 and 2022 consists of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Internal meeting	\$ 293,160	\$ 163,558
Public Relations	83,280	145,578
Fundraising expenses	149	-
Membership dues	9,370	3,982
Bank charges	23,612	15,638
Gift/Appreciation	167,845	47,583
Loss on disposal of fixed assets	2	1
Interest expense (PV)	-	7,220
Bad debt expenses	-	1,368,980
Others	640,855	23,010
	<u>\$ 1,218,273</u>	<u>\$ 1,775,550</u>

## 13. Liquidity

Financial assets which have remaining maturities within a year as of December 31, 2023 and 2022 consist of the following:

	<u>2023</u>	<u>2022</u>
(In U.S. Dollars)		
Cash and cash equivalents(*)	\$ 27,465,350	\$ 33,280,048
Bank deposits(*)	29,928,031	21,510,422
Contributions receivable	24,284,095	9,347,690
Other assets	361,627	360,925
	<u>\$ 82,039,103</u>	<u>\$ 64,499,085</u>

As part of the liquidity management, the IVI structures its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, the IVI invests cash in excess of operational requirements in short-term investments, bank time deposits. The IVI maintains undesignated funds within its net assets without donor restrictions which serve as operating reserve.

#### 14. Cash Flow Statement

Significant item in non-cash transactions occurring during current and prior periods is as below.

(In U.S. Dollars)	<u>2023</u>	<u>2022</u>
Accounts Payable for Tangible Assets Acquisition	\$ 336,604	\$ 43,009
	<u>\$ 336,604</u>	<u>\$ 43,009</u>

#### 15. Commitment

##### Commitment on acquisition of fixed asset and capital expenditure

Capital expenditure that was not recognized as liability which committed as of Dec 31, 2023 is following:

(In U.S. Dollars)	<u>Year</u>	<u>Capital Expenditure</u>
	2024	\$ 151,589
		<u>\$ 151,589</u>

Capital Expenditure committed as of end of current period includes Cage&Washer System Installation Contract amounting to US\$151,589.

##### Commitment on the contract

The IVI has a Sub-awards contract for supporting research and development and primary sub-awards expenditures that will be payable Dec 31 2023 henceforth are following:

(In U.S. Dollars)	<u>Year</u>	<u>Capital Expenditure</u>
	2024	\$ 4,698,277
	2025	\$ 2,186,346
	2026	\$ 1,081,279
		<u>\$ 7,965,901</u>